You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!Submit Review
Biological Activity for Flupenthixol dihydrochloride
Flupenthixol dihydrochloride is an antipsychotic drug. Exhibits antagonistic activity at dopamine D1-5 receptors. Used in schizophrenia treatment.
This compound is a mixture of E/Z isomers (ratio: 60:40).
Compound Libraries for Flupenthixol dihydrochloride
Technical Data for Flupenthixol dihydrochloride
|Storage||Desiccate at RT|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
Solubility Data for Flupenthixol dihydrochloride
|Solvent||Max Conc. mg/mL||Max Conc. mM|
Preparing Stock Solutions for Flupenthixol dihydrochloride
The following data is based on the product molecular weight 507.44. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||1.97 mL||9.85 mL||19.71 mL|
|5 mM||0.39 mL||1.97 mL||3.94 mL|
|10 mM||0.2 mL||0.99 mL||1.97 mL|
|50 mM||0.04 mL||0.2 mL||0.39 mL|
Product Datasheets for Flupenthixol dihydrochloride
References for Flupenthixol dihydrochloride
References are publications that support the biological activity of the product.
Peuch et al (1981) Pharmacological properties of new antipsychotic agents: Use of animal models. Neuropharmacology 20 1279 PMID: 6119637
If you know of a relevant reference for Flupenthixol dihydrochloride, please let us know.
View Related Products by Product Action
Keywords: Flupenthixol dihydrochloride, Flupenthixol dihydrochloride supplier, Flupenthixol, 2HCl, dopamine, receptor, antagonist, antipsychotic, drug, schizophrenia, Flupentixol, Non-selective, Dopamine, 4057, Tocris Bioscience
3 Citations for Flupenthixol dihydrochloride
Citations are publications that use Tocris products. Selected citations for Flupenthixol dihydrochloride include:
Schulz et al (2012) First and second generation antipsychotics influence hippocampal gamma oscillations by interactions with 5-HT3 and D3 receptors. Br J Pharmacol 167 1480 PMID: 22817643
FitzGerald et al (2014) A high through-put screen for small molecules modulating MCM2 phosphorylation identifies Ryuvidine as an inducer of the DNA damage response. PLoS One 9 e98891 PMID: 24902048
Regna et al (2016) A critical role for the Drosophila DA D1-like receptor Dop1R2 at the onset of metamorphosis. PLoS One 16 15 PMID: 27184815
Do you know of a great paper that uses Flupenthixol dihydrochloride from Tocris? Please let us know.
Reviews for Flupenthixol dihydrochloride
There are currently no reviews for this product. Be the first to review Flupenthixol dihydrochloride and earn rewards!
Have you used Flupenthixol dihydrochloride?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Dopamine Receptors Scientific Review
Written by Phillip Strange and revised by Kim Neve in 2013, this review summarizes the history of the dopamine receptors and provides an overview of individual receptor subtype properties, their distribution and identifies ligands which act at each receptor subtype. Compounds available from Tocris are listed.
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.
Schizophrenia is a debilitating psychiatric disorder that affects 1% of the worldwide population. This poster describes the neurobiology of Schizophrenia, as well as highlighting the genetic and environmental factors that play a fundamental role in the etiology of the disease. The current and emerging drug targets are also discussed.